Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of astegolimab for long-term safety in chronic obstructive pulmonary disease
MOH_2023-05-21_012651Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of astegolimab in chronic obstructive pulmonary disease (COPD), sponsored by Roche. Planned start May 2023; status: not yet recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2023-05-21_012651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-21_012651.